Should You Come To Envita for Late Stage or Early Stage Cancer?
From our two decades of clinical experience treating late and early-stage cancer patients, it has become apparent that the sooner you can incorporate precision targeting into your treatment plan, the better are your chances of a holistic recovery. Dr. Dino Prato and Dr. John Oertle discuss how precision is evolving cancer treatment. Regardless of the stage of cancer, being able to precision target the treatment with the help of in-depth genomic analysis and advanced immunotherapy options, will give patients a greater chance at responding to care.
Disclaimer: Individual results will vary. Envita makes no guarantees for outcomes. Each patient case is unique. Please consult your doctor before making any changes to your medical treatment. Not every patient is a candidate for care or achieves these results. Treatments used in this case may not all be FDA approved for the treatment of this condition.
In life-threatening diseases like cancer, timing is crucial, which highlights why getting access to new treatments and next-level healthcare technology matters in cancer care! The earlier you get access to these precision care options, the better are your chances of improving your quality of life, increasing longevity, and reducing toxicities and side effects, typically associated with the conventional one-size-fits-all cancer treatment options.
Effective Treatment in Early Stage Reduces Chances of Metastasis
Conventional treatments in National Cancer Institute (NCI)- designated cancer centers are based on a patient's cancer type and stage. These one-size-fits-all protocols, as determined typically by the NCCN (National Comprehensive Cancer Network) guidelines, allow access to precision only as a follow-up to failed first line treatments. However, at Envita Medical Centers and Center of Excellence, every patient gets access to detailed precision oncology, right at the beginning of care. Less than 20% of cancer patients in standard cancer centers, receive testing in precision oncology, and the testing that is available is often a watered-down version compared to what Envita offers. We aim to potentiate outcomes by going beyond the standard conventional treatments and clinical trials, by testing and treating the genetic, epigenetic, and several other factors contributing to each patient's cancer and its microenvironment. Our advanced precision algorithms remove the guesswork involved in traditional cancer treatment, allowing precision deployment of care. In our clinical opinion, incorporating precision oncology early in your treatment plan can be more effective, as it helps sustain lasting outcomes and minimizes chances of recurrence or metastatic spread.
Our genomic testing, which is a part of precision oncology, helps in gathering detailed bioinformatics data about each patient's specific cancer and the factors influencing its growth and proliferation. Absence of this data makes it difficult to create an effective treatment plan, which has the potential to reduce chances of metastasis, as metastasis in cancer patients. While Envita is known for its expertise in treating late-stage cancer, in our clinical experience, incorporating precision targeting as early as possible can be the key to successful cancer treatment.
For example, Envita's personalized precision oncology works in early-stage breast cancer by utilizing detailed genetic testing and genomic identification, which helps in precise-targeting of each patient's cancerous cells without impacting the surrounding healthy cells. Monitoring each patient's cancer biomarkers and their changing genetic mutations, allows our team of physicians to not just impact the disease and its cause, but also proactively treat it to reduce chances of potential metastasis to nearby or other distant parts of the body. With our Ultra Analytes Liquid Biopsy, we attempt to analyze the circulating tumor cells (CTCs) in a patient's blood stream for identifying and proactively treating signs of early metastasis.
Tumors in the breast can release cancerous cells that can spread to the lymph nodes or bloodstream, leading to micro metastatic disease. However, with conventional treatments in standard cancer centers, these signs of micro metastatic disease are often missed since the focus is on removing the mass without taking into account the potential spread of cancer cells.
Precision Oncology has the Potential to be a Gamechanger in Late-Stage Cancers
At Envita, we not only identify the early signs, but we also effectively treat it with several proprietary treatments, such as GTFC™ (Genetically Targeted Fractionated Chemotherapy) and CIPI™ (Chemo Immuno Precision Injections). CIPI™ is one of our minimally invasive, interventional radiology procedures which utilizes genomics and immuno targeting for stimulating the immune system to seek out and attack cancer cells, while GTFC™ is administered intravenously to maximize the mechanism of action against the cancerous cells, without severely impacting the surrounding healthy cells. In addition, we can also freeze the tumor, reducing or even eliminating the need for surgery, radiation, or chemotherapy.
The specially trained team at Envita utilizes advanced precision algorithms to remove the guesswork involved in traditional cancer treatments. Typically, cancer patients have to wait for imaging results to determine the efficacy of the treatments, but Envita's personalized precision oncology approach involves constant testing and monitoring of patients' responses using tools such as advanced imaging or CT-free DNA. Based on the results of these detailed analyses of each patient's specific cancer and their responses to treatments, doctors can modify or maintain care regimens.
This level of detailed diagnostics and custom-developed care protocols have the potential of providing lifesaving options to patients. Despite being refractory to care in major cancer treatment centers of the country, many patients, even with late-stage cancers, have experienced successful recoveries with our advanced precision genomic, immunotherapy options, and personalized drug design.
Our team of specially trained and board-certified oncologists, interventional radiologists, researchers, and pharmacists, work in unison to help you take advantage of our unique precision integrative oncology, which combines the benefits of conventional as well as integrative medicine. To help potentiate outcomes even in late-stage disease, we utilize a combination of FDA approved drugs, repurposed drugs, and custom compounded adjuvants, based on advanced phytotherapeutics, and made at our in-house pharmacy. If you or a loved one is facing a cancer diagnosis, please feel free to reach out to us at 866-830-4576. May God bless you on your journey to recovery!
